Axicabtagene Ciloleucel
Antineoplastic Cell and Gene Therapy
Sold as Yescarta
- Drug class
- Antineoplastic Cell and Gene Therapy
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 3
Overview
Axicabtagene Ciloleucel is an active pharmaceutical ingredient in the Antineoplastic Cell and Gene Therapy group (L01XL). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| EU European Union | EMA | 1 | May 19, 2026 |
| CA Canada | Health Canada | 1 | January 8, 2026 |
| GB United Kingdom | MHRA | 1 | May 15, 2026 |
EUEuropean Union· EMA
1 product
Uses
Yescarta is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. 3 Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.
How to take
CACanada· Health Canada
1 product
Uses
YESCARTA (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for: • the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
• the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), HGBL, and DLBCL arising from follicular lymphoma.
• the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy. 1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
2 Geriatrics No clinically important differences in safety or effectiveness were observed between patients aged 65 years and older compared to patients overall.
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Axicabtagene Ciloleucel. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]European Medicines Agency · EMEA/H/C/004480 · revised May 19, 2026
- [2]Health Canada (DPD) · 02485648 · revised January 8, 2026
- [3]MHRA (UK) · PLGB119720044 · revised May 15, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.